logo

For the Inventor, By the Inventor

Tenafly, NJ, United States of America

Stephen P Goff

USPTO Granted Patents = 12

Average Co-Inventor Count = 2.4

ph-index = 4

Forward Citations = 147(Granted Patents)


Location History:

  • Tenafly, NJ (US) (1990 - 2004)
  • New York, NY (US) (2020)

Company Filing History:

goldMedal12 out of 2,489 
 
Columbia University
 patents
silverMedal1 out of 1,210 
 
Dana-Farber-Cancer Institute Inc.
 patents
where one patent can have more than one assignee

Years Active: 1990-2020

Loading Chart...
12 patents (USPTO):Explore Patents
1. 10562939 - Method for significantly increasing lentiviral production (2020-02-18),
2. 6812025 - Two hybrid assay that detects HIV-1 reverse transcriptase dimerization (2004-11-02),
3. 6469153 - EIP-1 and EIP-3 genes, envelope-interacting proteins, EIP-1 and EIP-3 (2002-10-22),
4. 6372502 - Retroviral packaging cell lines and processes of using same (2002-04-16),
5. 6222024 - Nucleic acids encoding a human immunodeficiency virus type 1 (HIV-1) integrase interactor protein (INI-1) (2001-04-24),
6. 6136582 - Reverse transcriptase of moloney murine leukemia virus with RNA (2000-10-24),
7. 5872213 - Identification and characterization of a novel human protein designated (1999-02-16),
8. 5773225 - Screening method for the identification of compounds capable of (1998-06-30),
9. 5278056 - Retroviral packaging cell lines and process of using same (1994-01-11),
10. 5256554 - Expression of human immunodeficiency virus (HIV) reverse transcriptase (1993-10-26),
11. 5202259 - Expression of human immunodeficiency virus (HIV) reverse transcriptase (1993-04-13),
12. 4943531 - Expression of enzymatically active reverse transcriptase (1990-07-24),

Title: The Innovative Contributions of Stephen P. Goff

Introduction

Stephen P. Goff is a prominent inventor based in Tenafly, NJ (US), known for his significant contributions to the field of virology. With a total of 12 patents, Goff has made remarkable strides in understanding and manipulating viral production processes, particularly in relation to lentiviruses.

Latest Patents

Among his latest patents, Goff has developed a method for significantly increasing lentiviral production. This innovative approach involves inhibiting or preventing Heme Oxygenase 2 (HO-2) from binding to the group-specific antigen (Gag) of viral proteins. By allowing the delivery of viral proteins to plasma membranes, the replication and maturation of these proteins can occur without interference from HO-2. This invention is particularly applicable to the production of lentiviruses where the Matrix domain (MA) of the Gag is myristoylated. Another notable patent involves a two-hybrid assay that detects HIV-1 reverse transcriptase dimerization. This invention provides methods to determine whether a compound inhibits or enhances the formation of complexes between various subunit polypeptides of HIV-1 reverse transcriptase.

Career Highlights

Goff has had a distinguished career, working with esteemed institutions such as Columbia University and Dana-Farber Cancer Institute Inc. His research has significantly advanced the understanding of viral mechanisms and has implications for therapeutic developments.

Collaborations

Throughout his career, Goff has collaborated with notable colleagues, including Naoko Tanese and Arthur Bank. These collaborations have further enriched his research and contributed to the scientific community's understanding of viral biology.

Conclusion

Stephen P. Goff's innovative work in virology, particularly in the production and manipulation of lentiviruses, showcases his expertise and dedication to advancing scientific knowledge. His contributions continue to have a lasting impact on the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…